In conclusion, we are first reporting on comparison between standard chemo-immunotherapy with platinum-pemetrexed-pembrolizumab versus platinum-doublet alone front-line approach in patients with non-squamous NSCLC and PD-L1<50%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.